{"nctId":"NCT03353740","briefTitle":"Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence","startDateStruct":{"date":"2017-09-20","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":346,"armGroups":[{"label":"Ga-68 labeled PSMA-11 PET","type":"EXPERIMENTAL","interventionNames":["Drug: Ga-68 labeled PSMA-11 PET"]}],"interventions":[{"name":"Ga-68 labeled PSMA-11 PET","otherNames":["Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED-CC","Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC","Ga-68 labeled HBED-CC PSMA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Histopathologically proven prostate adenocarcinoma.\n* Rising prostate-specific antigen (PSA) (at least two consecutive rising PSAs) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).\n\n  * Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation for biochemical recurrence after radical prostatectomy\n\n    * PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.\n  * Post-radiation therapy -ASTRO-Phoenix consensus definition of biochemical recurrence after radiation therapy\n\n    * Nadir + greater than or equal to 2 ng/mL rise in PSA\n* Karnofsky performance status of \\> 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent).\n* Age \\>= 18.\n* Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria\n\n* Unable to lie flat, still or tolerate a PET scan.\n* Concomitant investigational therapy.\n* Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.\n* Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed if Furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device).","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up","description":"The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the lymph nodes using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy, clinical and conventional imaging follow-up. Corresponding two-sided 95% confidence intervals will be constructed using the Wilson score method.","classes":[]},{"type":"PRIMARY","title":"True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up","description":"The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the visceral tissue using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy, clinical and conventional imaging follow-up. Corresponding two-sided 95% confidence intervals will be constructed using the Wilson score method.","classes":[]},{"type":"PRIMARY","title":"True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up","description":"The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the bone tissue using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy, clinical and conventional imaging follow-up. Corresponding two-sided 95% confidence intervals will be constructed using the Wilson score method.","classes":[]},{"type":"PRIMARY","title":"True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up","description":"The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the prostate bed using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy, clinical and conventional imaging follow-up. Corresponding two-sided 95% confidence intervals will be constructed using the Wilson score method.","classes":[]},{"type":"SECONDARY","title":"Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.","description":"Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the lymph nodes as confirmed by by histopathology/biopsy, clinical and conventional imaging follow-up.","classes":[]},{"type":"SECONDARY","title":"PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.","description":"Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in visceral tissue as confirmed by by histopathology/biopsy, clinical and conventional imaging follow-up.","classes":[]},{"type":"SECONDARY","title":"PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.","description":"Positive predictive value is the probability that participants with a positive reading truly have prostate cancer metastasized in the bone as confirmed by by histopathology/biopsy, clinical and conventional imaging follow-up.","classes":[]},{"type":"SECONDARY","title":"PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.","description":"Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the prostate bed as confirmed by by histopathology/biopsy, clinical and conventional imaging follow-up.","classes":[]},{"type":"SECONDARY","title":"True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only","description":"The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the lymph nodes using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null}]}]}]},{"type":"SECONDARY","title":"True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only","description":"The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the visceral tissue using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null}]}]}]},{"type":"SECONDARY","title":"True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only","description":"The true positive rate or detection rate (sensitivity) is defined as the proportion of all participants who have prostate cancer detected in the bone tissue using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]}]},{"type":"SECONDARY","title":"True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only","description":"The true positive rate or detection rate is defined as the proportion of all participants who have prostate cancer detected in the prostate bed using Ga68-PSMA-11, where disease location is also confirmed by histopathology/biopsy only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":null}]}]}]},{"type":"SECONDARY","title":"PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only","description":"Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the lymph nodes as confirmed by by histopathology/biopsy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only","description":"Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the visceral tissue as confirmed by by histopathology/biopsy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null}]}]}]},{"type":"SECONDARY","title":"PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only","description":"Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the bone tissue as confirmed by by histopathology/biopsy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]}]},{"type":"SECONDARY","title":"PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only","description":"Positive predictive value is the probability that participants with a positive reading truly have prostate cancer in the prostate bed as confirmed by by histopathology/biopsy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value","description":"Detection rate (sensitivity) on a per-patient basis of 68Ga-PSMA-11 PET stratified by PSA value (0.2- \\<0.5, 0.5 - \\<1.0, 1.0 - \\<2.0, 2.0 - \\<5.0, \\>=5.0) will be summarized in tabular format for participants with PSMA positive disease, independent of pathology, imaging or clinical follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment","description":"Detection rates (sensitivity) on a per-patient basis of 68Ga-PSMA-11 PET stratified by prior cancer treatment (Prostatectomy, Radiation, or Prostatectomy plus Radiation) will be summarized in tabular format.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)","description":"Detection rate (sensitivity) on a per-patient basis of 68Ga-PSMA-11 PET stratified by prior use of ADT as a cancer treatment (Prior treatment with ADT, No prior treatment with ADT) will be summarized in tabular format.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With a Change in Clinical Management","description":"Impact of 68Ga-PSMA-11 PET on clinical management in patients with biochemical recurrence (BCR) was measured using Pre-PET (Q1), post-PET (Q2), and post-treatment (Q3) questionnaires sent to referring physicians recording site of recurrence and intended (Q1 to Q2 change) and implemented (Q3) therapeutic and diagnostic management. Percentage of participants with a change in clinical management will be reported using descriptive statistics based on qualitative physician responses from the change in management surveys.","classes":[]},{"type":"SECONDARY","title":"Rate of Inter-reader Reproducibility for Positivity","description":"Inter-reader reproducibility for positivity at the patient level will be reported using the Fleiss' Kappa test for multiple readers","classes":[]},{"type":"SECONDARY","title":"Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","description":"All grade 3 and above adverse events will be recorded using the NCI CTCAE v4.0. The Investigator will assign attribution of the possible association of the event with use of the investigational drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":346},"commonTop":[]}}}